Xceleron Services

Accelerating The Drug Development Process

Xceleron’s clinical research services help pharmaceutical and biotechnology clients to accelerate the drug development process and de-risk later clinical trial phases.

Clinical research teams turn to us to help them choose the best drug candidates before entering the clinical stages of pharmaceutical development, as well as to complete their regulatory submissions cost effectively and to problem-solve pharmacokinetic issues throughout the drug development process.

De-risking Later Stages of Drug Development

Using the enabling technology of accelerator mass spectrometry (AMS), Xceleron can detect and quantitate tiny traces of ¹⁴C-labeled drug, allowing for innovative clinical designs and analytical solutions unlike any other approach.

• Use our Phase0/Microdosing Services to select the best candidate prior to Phase I, or to answer key questions about your preclinical candidate
• Use the exquisite sensitivity of the AMS technology to support Preclinical Analysis for biologics or high potency drugs
• Gain human bioavailability data without needing formal intravenous (IV) formulation development using our IVPK Service
• Use our Solution to MIST Service to gain low cost human metabolite profiling data with just incremental cost on a standard Phase I study.
• Perform regulatory ADME/Mass Balance studies with vastly reduced manufacturing and toxicity/dosimetry regulatory requirements.

Delivering Cost and Timeline Savings

The cost and drug development timeline savings from our approach can be considerable. Drug researchers can save up to one year in clinical development time by using our AMS approach for a mass balance/ADME study, for example.